XML 21 R3.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Balance Sheet - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 8,077 $ 8,524
Accounts receivable, less allowances of $193 and $189 8,221 8,115
Inventories 5,088 5,634
Contract assets, net 1,443 1,312
Other current assets 1,760 1,644
Total current assets 24,589 25,229
Property, plant and equipment, net 9,448 9,280
Acquisition-related intangible assets, net 16,670 17,442
Other assets 3,999 4,007
Goodwill 44,020 41,196
Total assets 98,726 97,154
Current liabilities:    
Short-term obligations and current maturities of long-term obligations 3,609 5,579
Accounts payable 2,872 3,381
Accrued payroll and employee benefits 1,596 2,095
Contract liabilities 2,689 2,601
Other accrued expenses 3,246 3,354
Total current liabilities 14,012 17,010
Deferred income taxes 1,922 2,849
Other long-term liabilities 4,642 4,238
Long-term obligations 31,308 28,909
Commitments and Contingencies
Redeemable noncontrolling interest 118 116
Thermo Fisher Scientific Inc. shareholders’ equity:    
Preferred stock, $100 par value, 50,000 shares authorized; none issued
Common stock, $1 par value, 1,200,000,000 shares authorized; 442,188,634 and 440,668,112 shares issued 442 441
Capital in excess of par value 17,286 16,743
Retained earnings 47,364 41,910
Treasury stock at cost, 55,541,290 and 50,157,275 shares (15,133) (12,017)
Accumulated other comprehensive income/(loss) (3,224) (3,099)
Total Thermo Fisher Scientific Inc. shareholders’ equity 46,735 43,978
Noncontrolling interests (11) 54
Total equity 46,724 44,032
Total liabilities, redeemable noncontrolling interest and equity $ 98,726 $ 97,154